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Despite the high prevalence of chronic kidney disease among
the elderly, few studies have described their loss of kidney
function. We sought to determine the progression of kidney
dysfunction among a community-based cohort of elderly
subjects. The cohort included 10 184 subjects 66 years of age
or older, who had one or more outpatient serum creatinine
measurements during each of two time periods: 1 July to 31
December 2001 and 1 July to 31 December 2003. A mixed
effects model, including covariates for age, gender, diabetes
mellitus, and comorbidity, was used to determine the rate of
decline in estimated glomerular filtration rate (eGFR, in ml/
min/1.73 m2) per year over a median follow-up of 2.0 years.
Subjects with diabetes mellitus had the greatest decline in
eGFR of 2.1 (95% CI 1.8–2.5) and 2.7 (95% CI 2.3–3.1) ml/min/
1.73 m2 per year in women and men, respectively. The rate of
decline for women and men without diabetes mellitus was
0.8 (95% CI 0.6–1.0) and 1.4 (95% CI 1.2–1.6) ml/min/1.73 m2
per year. Subjects with a study mean eGFRo30 ml/min/
1.73 m2, both those with and without diabetes mellitus,
experienced the greatest decline in eGFR. In conclusion, we
found that the majority of elderly subjects have no or
minimal progression of kidney disease over 2 years.
Strategies aimed at slowing progression of kidney disease
should consider underlying risk factors for progression and
the negligible loss of kidney function that occurs in the
majority of older adults.
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The prevalence of end-stage renal disease continues to grow
worldwide. Given the health care costs, impaired quality of
life, and decreased life expectancy, the patient and societal
burden associated with end-stage renal disease is enormous.
In both Canada1 and the United States,2 subjects aged 65 and
older are the most rapidly growing segment of the population
starting dialysis.
Underlying these numbers in the end-stage renal disease
population is a high prevalence of Stage 3 and 4 chronic
kidney disease (CKD) in the elderly, with rates of 253 to 55%.4
Recognizing that reduced kidney function in this age group is
a marker for poor outcomes, including de novo cardiovascular
disease and decreased survival,5–10 emphasis has been placed
on early detection and implementation of strategies to slow
the progression of CKD,11 despite limited understanding of
the rate of progression of CKD. While rates of loss of kidney
function commonly referred to in the literature are as high as
7–8 ml/min/year,12 these estimates are based on select patient
populations typically enrolled in clinical trials. Few studies
have described the progression of CKD in older community-
based individuals, and to the best of our knowledge none have
confirmed the widely held belief that low GFR is associated
with a rapid progression of kidney dysfunction in the elderly.
This is particularly relevant given their high prevalence of
CKD and the significant resources invested to slow the
progressive loss of kidney function, a primary objective of care
for patients with CKD. A better understanding of the expected
rate of progression of CKD would enable more targeted
provision of care, particularly in older subjects in whom the
burden of kidney disease is the greatest.
Using a prospective study design, we sought to describe
the rate of progression of kidney dysfunction among a
community-based cohort of subjects 66 years of age and
older, and assess the degree of progression by stage of CKD.
RESULTS
We identified 12 641 subjects 66 years of age and older who
had at least one outpatient measurement of serum creatinine
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in each of the two time periods (1 July 2001 to 31 December
2001, and 1 July 2003 to 31 December 2003), and who were
not on dialysis on their index date. We excluded 2457
subjects (19.4%), as outlined in Figure 1, for a final study
population of 10 184. The majority of subjects (64.5%) had a
study mean estimated glomerular filtration rate (eGFR) (ml/
min/1.73 m2) of 60–89, while 31.3 and 4.1% had a study
mean eGFR of 30–59 and o30, respectively. The median
number of creatinine measurements during the study period
was 3 (interquartile range, 2–4), with a median duration of
follow-up between the first and last serum creatinine
measurement of 2.0 years (interquartile range, 1.9–2.2).
Overall, the 10 184 subjects contributed 24 525 person-years
of follow-up.
As outlined in Table 1, subjects with a higher study mean
eGFR (60–89 ml/min/1.73 m2) were slightly younger and
more likely to be male, while subjects with a low study mean
eGFR (o30 ml/min/1.73 m2) were more likely to have
diabetes mellitus and a higher comorbidity score (indicating
increased comorbidity). Subjects with a low study mean
eGFR were also more likely to have had a prescription for an
angiotensin converting enzyme-inhibitor or angiotensin
receptor blocker, a beta-blocker, a lipid lowering agent, and
a diuretic in the year prior to their index date. Despite the
reduction in their kidney function, 30.0% of subjects with a
study mean eGFRo30 ml/min/1.73 m2 were prescribed a
nonsteroidal anti-inflammatory drug in the prior year.
During follow-up, 87 (0.9%) subjects began dialysis, 81
(93.1%) of whom were from the group with a study mean
eGFRo30 ml/min/1.73 m2. Also during follow-up 239 sub-
jects died, with the death rate highest (6.0%) for subjects
with a study mean eGFRo30 ml/min/1.73 m2.
Rate of decline in eGFR ml/min/1.73 m2 per year
The results of the mixed-effects model, which takes into
account the varying number and spacing of eGFR measure-
ments and variable follow-up for each subject, are shown in
Table 2. After adjustment for age, males with diabetes
mellitus experienced the greatest overall decline in eGFR of
2.7 ml/min/1.73 m2 per year (95% CI 2.3–3.1). Females with
diabetes mellitus also experienced a significant decline in
eGFR of 2.1 ml/min/1.73 m2 per year (95% CI 1.8–2.5). Male
and female subjects without diabetes also experienced a
significant, but smaller, decline in eGFR of 1.4 ml/min/
1.73m2 per year (95% CI 1.2–1.6) and 0.8 ml/min/1.73m2 per
year (95% CI 0.6–1.0), respectively. When stratified by study
mean eGFR categories, the rate of decline in eGFR increased
as eGFR decreased. In a sensitivity analysis including subjects
with a study mean eGFRX90 ml/min/1.73 m2, the overall
rate of decline was slightly lower, while the rates of decline
stratified by study mean eGFR were nearly identical. Similar
results were obtained when subjects with more than 12 serum
creatinine measurements in either time period (n¼ 182) were
included.
12,641 subjects with  
at least one serum creatinine in   
July 1 2001 to December 31 2001 and 
July 1 2003 to December 31 2003 
Exclude 182 with >12 serum creatinine
measurements in either time period  
10,184 subjects included in final cohort 
Exclude three with pre-emptive kidney
transplant prior to July 1 2003 
Exclude 2272 with study mean
eGFR>90 ml/min/1.73 m2
Figure 1 | Formation of study cohort and reasons for exclusion.
Table 1 | Baseline characteristics of subjects by study mean eGFR
Characteristics
60–89 ml/min/1.73 m2
(N=6573)
30–59 ml/min/1.73 m2
(N=3191)
o30 ml/min/1.73 m2
(N=420) P*
Age, mean (s.d.) 75.1 (6.4) 77.8 (6.9) 77.5 (6.8) o0.001
Female gender (%) 54.9 62.5 57.6 o0.001
Diabetes mellitus (%) 14.2 19.8 31.0 o0.001
Comorbidity score, median (interquartile range) 2143 (1506–2992) 2745 (2001–3729) 3468 (2227–4704) o0.001
Drug use in prior year (%)
ACE-I/ARBa 35.7 52.7 65.2 o0.001
Beta blocker 19.8 27.7 35.5 o0.001
Lipid lowering 22.3 26.6 34.3 o0.001
Diuretics 29.1 50.1 62.9 o0.001
NSAIDs 34.0 37.7 30.0 o0.001
*P calculated by w2 test for categorical variables, ANOVA for age, and Kruskal–Wallis test for comorbidity score.
aACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; ANOVA, analysis of variance.
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Absolute change in mean eGFR
Consistent with the results of the mixed-effects model, when
progression of kidney function was assessed by absolute
change in mean eGFR (mean eGFR 2001mean eGFR 2003),
subjects with diabetes mellitus showed the greatest decline in
eGFR over the 2-year period, with a change in mean eGFR
(95% CI) of 4.2 (3.2–5.2) and 5.1 (4.1–6.0) for female and
male subjects, respectively (Table 3). When stratified by study
mean eGFR categories, the degree of progression increased as
eGFR declined. Similar to the analyses of the rate of decline,
the greatest absolute change in mean eGFR was for subjects
with a study mean eGFRo30 ml/min/1.73 m2, both those
with and without diabetes mellitus. Similar results were
obtained in an analysis stratified by use of angiotensin
converting enzyme-inhibitors and/or angiotensin receptor
blockers. Over the 2-year study period, 41% of subjects had
an increase in their mean eGFR (median (inter-quartile
range) increase of 7.0 (3.0–12.7) ml/min/1.73 m2).
Percent change in mean eGFR
Similar results were seen using median percent change in
mean eGFR as the end point, where subjects with diabetes
mellitus had the greatest percent decline in eGFR across all
categories of study mean eGFR over the 2-year period
(Table 3). The results of this analysis further demonstrate the
greatest decline in eGFR for female and male subjects with a
study mean eGFRo30 ml/min/1.73 m2, particularly among
subjects with diabetes mellitus (median percent change in
mean eGFR of 27.6% (95% CI 19.1–34.6%) and 20.1% (95%
CI 12.0–29.0%), respectively).
Categorical change in kidney function
Change in mean eGFR between 2001 and 2003 was also
divided into five categories, in ml/min/1.73 m2 (p0, 1–5,
6–10, 11–15, and 415) to further assess degree of progression
of kidney dysfunction by study mean eGFR (Figure 2). The
majority of subjects (greater than 50%) in each of the three
study mean eGFR groups had a change in mean eGFR of
5 ml/min/1.73 m2 or less over the 2-year study period. A
change in mean eGFR of 415 ml/min/1.73 m2 was experi-
enced by 13.6% of subjects with study mean eGFR 60–89,
13.2% of subjects with study mean eGFR 30–59, and 8.6% of
subjects with study mean eGFRo30.
DISCUSSION
The majority of elderly subjects in this large community-
based study had minimal or no progression of kidney disease
over a median follow-up of 2 years. The progressive nature of
CKD among subjects with diabetes mellitus is not a novel
finding, but validates our results given the consistency with
prior reports.13–17 At lower levels of baseline kidney function,
the degree of progression also increased, particularly for
subjects with a study mean eGFRo30 ml/min/1.73 m2.
Table 2 | Age-adjusted rate of decline in eGFR ml/min/1.73 m2 per year (95% confidence interval)
Subject characteristics Study mean eGFR 60–89 Study mean eGFR 30–59 Study mean eGFRo30 Overall
Females without diabetes mellitus 0.6 (0.3–0.9) 1.1 (0.8–1.4) 1.8 (1.2–2.4) 0.8 (0.6–1.0)
Males without diabetes mellitus 1.1 (0.8–1.4) 1.9 (1.5–2.3) 2.0 (1.3–2.7) 1.4 (1.2–1.6)
Females with diabetes mellitus 1.6 (1.0–2.1) 2.8 (2.3–3.3) 2.9 (2.2–3.7) 2.1 (1.8–2.5)
Males with diabetes mellitus 2.1 (1.6–2.6) 3.6 (3.1–4.2) 3.2 (2.3–4.0) 2.7 (2.3–3.1)
eGFR, estimated glomerular filtration rate.
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Figure 2 | Categorical change in mean eGFR (2001–2003) by
patient study mean eGFR.
Table 3 | Absolute change and percent change in mean eGFR over the study period, by study mean eGFR
Subject characteristics Study mean eGFR 60–89 Study mean eGFR 30–59 Study mean eGFRo30 Overall
Absolute change in mean eGFR ml/min/1.73 m2 (95% confidence interval)
Females without diabetes mellitus 1.1 (0.6–1.6) 2.0 (1.4–2.6) 3.0 (1.8–4.3) 1.5 (1.1–1.9)
Males without diabetes mellitus 2.3 (1.8–2.9) 3.5 (2.7–4.3) 4.3 (2.7–4.3) 2.7 (2.3–3.1)
Females with diabetes mellitus 2.0 (1.5–4.7) 5.1 (3.8–6.3) 6.5 (4.7–8.3) 4.2 (3.2–5.2)
Males with diabetes mellitus 3.8 (2.4–5.2) 7.2 (5.9–8.6) 5.1 (3.0–7.1) 5.1 (4.1–6.0)
Percent changea in mean eGFR ml/min/1.73 m2 (95% confidence interval)
Females without diabetes mellitus 1.4% (0.0–2.2%) 3.6% (2.4–5.1%) 11.7% (7.1%–16.4%) 2.3% (1.6–2.8%)
Males without diabetes mellitus 2.8% (2.2–3.5%) 4.2% (3.0–5.6%) 15.5% (8.0%–20.4%) 3.5% (2.8–4.0%)
Females with diabetes mellitus 2.8% (0.4–4.0%) 8.6% (6.5–11.3%) 27.6% (19.1%–34.6%) 6.5% (4.5–8.1%)
Males with diabetes mellitus 3.9% (2.4–5.9%) 11.7% (9.1–15.0%) 20.1% (12.0%–29.0%) 7.1% (5.7–8.7%)
aMedian percent change.
eGFR, estimated glomerular filtration rate.
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The importance of studying the progression of CKD
among community dwelling subjects, particularly to guide
recommendations for health policy and management of
CKD, has been emphasized.18 Our current understanding of
the progression of CKD is based on observational studies and
randomized trials conducted in patients referred for specialist
care, with rates of eGFR loss of approximately 7–8 ml/min/
year.12 Results from our current study and other community-
based reports indicate a much lower rate of eGFR loss in the
elderly. In a smaller study of a select male sample, the
Baltimore Longitudinal Study on Aging19 reported an average
decline in creatinine clearance of 0.75 ml/min per year after
the third decade of life, with approximately one-third of
subjects demonstrating stable kidney function over 20 years
of follow-up. Although eGFR was not calculated, results from
the Cardiovascular Health Study also indicate little or no
progression of CKD in the majority of older adults; a
deterioration in kidney function of 426.5 mmol/l (0.3 mg/dl)
was seen in less than 3% of the subjects (mean age 73 years),
who were followed for at least 3 years.20
Progression of kidney disease has also been examined in
the setting of other observational studies and clinical trials.
Compared to our study, these reports involved fewer
numbers of subjects,21–25 analyzed a dichotomous outcome
for loss of kidney function,22,23 or were potentially influenced
by referral22 or selection bias.21,24,25 None of these studies
described the loss of kidney function solely in older
participants.
The increased risk of death, as opposed to dialysis, was
also evident in our study with a risk of death 6–60-times
greater than the risk of dialysis in subjects with a study mean
eGFR of 30–59 and 60–89 ml/min/1.73m2, respectively.
These results are consistent with a prior study26 based on
28 000 Health Maintenance Organization enrollees (mean age
65) with a baseline eGFRo90 ml/min/1.73 m2 followed for
5 years, where death was far more common than dialysis at all
stages of kidney function.
In the current study, the low rate of progression of kidney
dysfunction in the majority of community-dwelling elderly
subjects without diabetes mellitus is reassuring given the high
prevalence of CKD in this population.3,4 However, the
higher rates of progression for subjects with study mean
eGFRo30 ml/min/1.73 m2, both with and without diabetes
mellitus, emphasize the importance of targeted provision of
care in patients with CKD. Although all CKD patients require
aggressive cardiovascular risk reduction,27 not all elderly
CKD patients require an emphasis on therapy to delay
progression of kidney disease. These high-risk patients can be
identified by the presence of diabetes mellitus, substantial
proteinuria,15,28–30 and as is evident in this study, a mean
eGFRo30 ml/min/1.73 m2. It is these same patients that are
likely to receive the most benefit with referral to specialized
and multidisciplinary care.31–33
Our study has a number of strengths, including the ability
to study community-dwelling subjects using eGFR to assess
kidney function and a measure of comorbidity. Specifically,
kidney function was estimated by the modification of diet in
renal disease (MDRD) prediction equation, which takes into
account subject age and gender. Use of serum creatinine
alone as an indirect measure of eGFR results in marked
under-recognition of kidney dysfunction among elderly
subjects.34–36
Several limitations of our study should be considered.
First, our study only included subjects who had a serum
creatinine measurement. Subjects with kidney dysfunction
who may be at the risk of progression yet did not have a
serum creatinine measurement would not be included. Given
that our study was based on the elderly, who are more likely
to access the health care system and have laboratory testing
completed, this is unlikely to substantially bias our study
results. This is further supported by a similar age distribution
in our study to that reported for the general population of
the Calgary Health Region (data not shown). In addition,
results from a cohort identified by laboratory-based case
finding are easily generalized to primary care practice. The
inclusion of study subjects with are least one serum
creatinine measurement in each of the study time periods
also increases generalizability. In a sensitivity analysis subjects
with more frequent measurements were more likely to have
diabetes mellitus, a lower study mean eGFR, a higher
comorbidity score, and a higher mortality rate. They were
also more likely to initiate dialysis during the study period.
Second, given that subjects required a serum creatinine
measurement in each of two time periods, survival bias may
have been introduced. While it is plausible that subjects at
greatest risk of progressing may have died prior to July 2003,
results of a sensitivity analysis comparing progression among
subjects who died in 2003 with those who survived revealed
similar rates of progression. Third, although serum creatinine
measurements were performed in the same laboratory,
eliminating the potential for inter-laboratory variation in
measurement, laboratory drift over the study period may
have influenced the study results. The impact of this potential
drift is expected to be minimal as we calibrated measure-
ments between the two time periods on a subset of healthy
subjects. We did not attempt to calibrate serum creatinine
measurements with the Cleveland Clinic laboratory from
which the MDRD equation was derived. Such calibration is
critical to estimate prevalence of kidney disease; however,
given our primary interest in the change of kidney function,
such calibration would not influence the overall study results.
Fourth, while 2 years may be viewed as an insufficient period
for follow-up, previous studies have demonstrated that this
duration is adequate to determine progression of kidney
function.37 Fifth, although we attempted to reduce the effect
of regression to the mean (which would have the greatest
influence for extreme values of eGFR) by using study mean
eGFR for each subject, residual effects may be present and
may bias the results towards the null. Sixth, our results are
generalizable to the elderly of Caucasian race, and not
to other age or racial groups. Finally, although we adjusted
for comorbidity based on medication use, this may
2158 Kidney International (2006) 69, 2155–2161
o r i g i n a l a r t i c l e BR Hemmelgarn et al.: Progression of kidney function in the elderly
underestimate the true prevalence of these conditions. In
addition, we were unable to adjust for blood pressure control,
presence of proteinuria, cause of kidney disease, smoking
status and lipid control, variables that may be associated with
decline in kidney function. Given that the aim of this study was
to describe progression of kidney dysfunction in a community-
based cohort, and not to define predictors of progression, lack
of information on these variables specifically would not change
the overall interpretation of the study results.
In conclusion, we found that the majority of community-
dwelling elderly subjects had no or minimal progression of
kidney disease over a 2-year period. Strategies aimed at
slowing progression of kidney disease should consider
underlying risk factors for progression and the negligible
loss of kidney function that occurs in the majority of older
adults. These results should impact recommendations for
referral to nephrologists and multidisciplinary nephrology
care clinics. Emphasis on cardiovascular risk reduction
should continue in all CKD patients.
MATERIALS AND METHODS
Study population
We identified a cohort of elderly subjects from the Calgary
Laboratory Services (CLS) computerized database, Alberta, Canada.
Calgary Laboratory Services provides laboratory testing for the
entire Calgary Health Region (catchment population 1.1 million)
using a single regional laboratory and standardized methods that are
recalibrated routinely against reference samples. To be eligible for
inclusion, subjects had to be 66 years of age or older and have had
one or more outpatient serum creatinine measurements during each
of two time periods, 1 July 2001 to 31 December 2001, and 1 July
2003 to 31 December 2003. To avoid episodes of acute renal failure
laboratory measurements associated with a hospital admission were
excluded. The first outpatient serum creatinine measurement
between 1 July 2001 and 31 December 2001 was used to define
the index GFR. Subjects who were already receiving dialysis at study
entry were excluded.
Using the unique provincial health care number for each subject,
laboratory data from study subjects were linked to provincial
administrative data to obtain information on prescription drug use
in the year prior to their index eGFR. All residents of Alberta aged
65 and older receive insured health services including coverage for
prescription drugs. To ensure availability of 1 year of drug data for
all subjects, entry into the study was limited to subjects 66 years of
age or older. Drug data were used to determine the presence of
diabetes mellitus, as defined by at least one prescription for
insulin or an oral hypoglycemic agent in the year prior to the
index eGFR, and to derive a measure of comorbidity based on the
Chronic Disease Score.38 The Chronic Disease Score is a weighted
index that takes into account the patient’s age, gender, and
diagnoses as derived from the classes of medications that are
used, with higher scores reflecting increased comorbidity. The
Chronic Disease Score has been validated and shown to correlate
with health care outcomes.38 Linkage to Alberta Bureau of Vital
Statistics was undertaken to obtain a date of death for subjects
who died between 1 July 2003 and 29 February 2004. The cohort was
also linked to the Southern Alberta Renal Program database39 to
identify subjects who started dialysis between their index eGFR
and 29 February 2004.
Measure of kidney function
We estimated GFR using the abbreviated modification of diet in
renal disease equation (MDRD-GFR),11 (eGFR¼ 186Pcr1.154
age0.203 1.212 [if black] 0.742 [if female]). Preliminary studies
have validated this equation in the elderly.40 Although data on race
were not available from the data sources, o1% of the Alberta
population is African American, and therefore the impact at the
population level of eliminating race from the estimate of GFR was
expected to be minimal. Moreover, given that we were interested in
change in eGFR, lack of information on race would not bias the
results. To reduce the effect of regression to the mean, a statistical
phenomenon that occurs when repeated measurements with wide
variability in results are made on the same subject,41–43 we calculated
the ‘study mean eGFR’ for each subject based on their serum
creatinine measurements over the entire study period. The study
mean eGFR, rather than the index eGFR, was used in the stratified
analysis.
Because of concerns about the validity of the MDRD eGFR
at higher levels of kidney function,44 we limited our study popu-
lation to those with a study mean eGFR of o90 ml/min/1.73 m2.
In a sensitivity analysis, we assessed the rate of decline in eGFR
in the entire cohort, including subjects with a study mean
eGFRX90 ml/min/1.73 m2. We also excluded subjects who had
more than 12 outpatient measurements of serum creatinine in either
of the 6 month observation periods, as they were likely to represent
patients with unstable kidney function. Patients with CKD who
underwent a pre-emptive kidney transplant prior to 1 July 2003
were also excluded. We classified baseline kidney function using the
National Kidney Foundation classification of CKD11: GFR 60–89
30–59; and o30 ml/min/1.73 m2.
Serum creatinine measurements were performed in the same
laboratory, thus eliminating the potential for inter-laboratory
variation in measurement. However, because of possible intra-
laboratory variation in measurement resulting from changes in
instrumentation and calibration of serum creatinine assays,
measurements between the two time periods were assessed and
calibrated in the following manner. First, a subset of healthy subjects
(defined as subjects with no prescriptions for medications
commonly used to treat cardiovascular disease, hypertension, or
diabetes mellitus in the year prior to the index eGFR) less than 80
years of age was identified. The median serum creatinine measure-
ment for these subjects, by 1-year age increments, for the 2001 and
the 2003 time periods was calculated. The difference between
measurements for the two periods was calculated, and the average of
the differences determined. To correct for the systematic differences
in serum creatinine measurements evident from this analysis,
2.0 mmol/l (0.02 mg/dl) was subtracted from the values of serum
creatinine measurements in 2003.
Statistical analysis
For the primary assessment of the progression of kidney function, we
determined the rate of decline in eGFR in ml/min/1.73 m2 per year,
using a mixed effects model with random intercepts and random
slopes. This model45,46 estimates the rate of change in eGFR over
time, taking into account the varying number and spacing of
measurements of eGFR, as well as the variable follow-up for each
subject. Potential covariates considered in the model included age,
gender, diabetes mellitus and comorbidity score. Age was entered as a
continuous variable and the comorbidity score was divided into
quartiles. Results are presented as the rate of change in eGFR per year.
Assumptions for the mixed-effects model were tested and satisfied.
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In a secondary analysis, we also determined the mean eGFR per
patient for each of the two time periods (1 July 2001 to 31 December
2001 and 1 July 2003 to 31 December 2003), and defined
progression as the absolute change in the mean eGFR between
2001 and 2003 (mean eGFR 2001mean eGFR 2003). The clinical
relevance of the absolute change in mean eGFR is highly dependent
on the baseline eGFR, as a decline in mean eGFR from 75 to 70 ml/
min/1.73 m2, for example, would have less clinical importance than
a decline in mean eGFR from 17 to 12 ml/min/1.73 m2, yet both
represent an absolute change of 5 ml/min/1.73 m2. Therefore, to take
baseline eGFR into account, the percent change in the mean eGFR
for the study period was also assessed ([mean eGFR 2001mean
eGFR 2003]/mean eGFR 2001). The transformation of mean eGFR
into percent change resulted in a non-normal distribution; there-
fore, these results are presented as median percent change in mean
eGFR. The results were further stratified by study mean eGFR,
gender, and diabetes mellitus.
The change in mean eGFR between the two periods was further
divided into five categories, in ml/min/1.73 m2 (p0, 1–5, 6–10, 11–15,
and 415), and stratified by study mean eGFR, to further compare the
degree of progression across the different categories of study mean eGFR.
All analyses were conducted with the use of SAS software
(version 8.01, SAS Institute Inc., Cary, NC, USA). The institutional
review board at the University of Calgary approved the study.
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